.Pharmacolibrary.Drugs.ATC.D.D11AH02

Information

Pimecrolimus is a topical calcineurin inhibitor used primarily in the treatment of atopic dermatitis (eczema). It acts as an immunomodulating agent that inhibits T-cell activation by blocking the production and release of pro-inflammatory cytokines and mediators from T-cells. Currently, it is approved for use in mild to moderate atopic dermatitis and is available in topical formulations.

Pharmacokinetics

Adults and children with atopic dermatitis treated topically with 1% pimecrolimus cream.

References

1. Draelos, Z, et al., & Paul, CF (2005). Pharmacokinetics of topical calcineurin inhibitors in adult atopic dermatitis: a randomized, investigator-blind comparison. Journal of the American Academy of Dermatology 53(4) 602–609. DOI:10.1016/j.jaad.2005.06.013 PUBMED:https://pubmed.ncbi.nlm.nih.gov/16198779

2. Staab, D, et al., & Burtin, P (2005). Low systemic absorption and good tolerability of pimecrolimus, administered as 1% cream (Elidel) in infants with atopic dermatitis--a multicenter, 3-week, open-label study. Pediatric dermatology 22(5) 465–471. DOI:10.1111/j.1525-1470.2005.00128.x PUBMED:https://pubmed.ncbi.nlm.nih.gov/16191004

Revisions

• 06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)